Posts

nTIDE October 2023 Jobs Report: People with disabilities maintain job gains as economy cools

nTIDE October 2023 Jobs Report: People with disabilitie...

Nov 3, 2023

East Hanover, NJ – November 3, 2023 – Experts reported little change in October’...

Illinois Tech grows research footprint, securing prime space at TCC’s Fulton Labs

Illinois Tech grows research footprint, securing prime ...

Nov 3, 2023

CHICAGO—November 3, 2023—Illinois Institute of Technology (Illinois Tech) has le...

Physicists ask: Can we make a particle collider more energy efficient?

Physicists ask: Can we make a particle collider more en...

Nov 3, 2023

Ever since the discovery of the Higgs boson in 2012, physicists have wanted to b...

Management of recurrent gastrointestinal cancer with ripretinib and surgery

Management of recurrent gastrointestinal cancer with ri...

Nov 3, 2023

“The patient was managed with ripretinib and surgical resection of progressing l...

FDA Advisors Greenlight First CRISPR-Based Therapy with Confidence in Off-Target Tests

FDA Advisors Greenlight First CRISPR-Based Therapy with...

Nov 2, 2023

FDA advisers have expressed contentment with CRISPR Therapeutics and Vertex Phar...

C4 Therapeutics Abandons Cancer Program and Awaits Payment from Betta

C4 Therapeutics Abandons Cancer Program and Awaits Paym...

Nov 2, 2023

C4 Therapeutics has made the decision to discontinue the development of one of i...

40% of patients respond to Deciphera’s tumor-fighting oral medication, setting up for 2024 submission

40% of patients respond to Deciphera’s tumor-fighting o...

Nov 2, 2023

Over three years following the initial approval of a pharmaceutical by Deciphera...

Camidanlumab tesirine by ADC Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval

Camidanlumab tesirine by ADC Therapeutics for Myelodysp...

Nov 2, 2023

Camidanlumab tesirine is under clinical development by ADC Therapeutics and curr...

AB-1003 by Asklepios BioPharmaceutical for Limb-Girdle Muscular Dystrophy: Likelihood of Approval

AB-1003 by Asklepios BioPharmaceutical for Limb-Girdle ...

Nov 2, 2023

AB-1003 is under clinical development by Asklepios BioPharmaceutical and current...

Darovasertib by Ideaya Biosciences for Colorectal Cancer: Likelihood of Approval

Darovasertib by Ideaya Biosciences for Colorectal Cance...

Nov 2, 2023

Darovasertib is under clinical development by Ideaya Biosciences and currently i...

GRWD-5769 by Grey Wolf Therapeutics for Solid Tumor: Likelihood of Approval

GRWD-5769 by Grey Wolf Therapeutics for Solid Tumor: Li...

Nov 2, 2023

GRWD-5769 is under clinical development by Grey Wolf Therapeutics and currently ...

APVO-436 by Aptevo Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval

APVO-436 by Aptevo Therapeutics for Myelodysplastic Syn...

Nov 2, 2023

APVO-436 is under clinical development by Aptevo Therapeutics and currently in P...

PRT-811 by Prelude Therapeutics for CNS Lymphoma: Likelihood of Approval

PRT-811 by Prelude Therapeutics for CNS Lymphoma: Likel...

Nov 2, 2023

PRT-811 is under clinical development by Prelude Therapeutics and currently in P...

Bezuclastinib by Cogent Biosciences for Systemic Mastocytosis: Likelihood of Approval

Bezuclastinib by Cogent Biosciences for Systemic Mastoc...

Nov 2, 2023

Bezuclastinib is under clinical development by Cogent Biosciences and currently ...

Rituximab biosimilar by Celltrion for Waldenstrom Macro...

Nov 2, 2023

Rituximab biosimilar is under clinical development by Celltrion and currently in...

Gebasaxturev by Merck for Oral Cavity (Mouth) Cancer: Likelihood of Approval

Gebasaxturev by Merck for Oral Cavity (Mouth) Cancer: L...

Nov 2, 2023

Gebasaxturev is under clinical development by Merck and currently in Phase II fo...